1. Home
  2. BWXT vs BBIO Comparison

BWXT vs BBIO Comparison

Compare BWXT & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BWX Technologies Inc.

BWXT

BWX Technologies Inc.

N/A

Current Price

$195.79

Market Cap

17.9B

Sector

N/A

ML Signal

N/A

Logo BridgeBio Pharma Inc.

BBIO

BridgeBio Pharma Inc.

N/A

Current Price

$71.45

Market Cap

15.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BWXT
BBIO
Founded
1867
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.9B
15.3B
IPO Year
2010
2019

Fundamental Metrics

Financial Performance
Metric
BWXT
BBIO
Price
$195.79
$71.45
Analyst Decision
Buy
Strong Buy
Analyst Count
9
24
Target Price
$204.60
$83.00
AVG Volume (30 Days)
740.8K
2.8M
Earning Date
05-26-2026
05-22-2026
Dividend Yield
0.55%
N/A
EPS Growth
16.61
N/A
EPS
3.58
N/A
Revenue
$1,687,738,000.00
$502,076,000.00
Revenue This Year
$18.90
$88.86
Revenue Next Year
$10.10
$74.11
P/E Ratio
$54.83
N/A
Revenue Growth
N/A
126.26
52 Week Low
$84.21
$28.33
52 Week High
$220.57
$84.94

Technical Indicators

Market Signals
Indicator
BWXT
BBIO
Relative Strength Index (RSI) 44.92 52.30
Support Level $187.01 $70.65
Resistance Level $218.46 $79.56
Average True Range (ATR) 9.08 3.33
MACD -1.44 0.67
Stochastic Oscillator 20.98 65.78

Price Performance

Historical Comparison
BWXT
BBIO

About BWXT BWX Technologies Inc.

BWX Technologies Inc is a specialty manufacturer and service provider of nuclear components, operating in two segments: Government Operations and Commercial Operations. The Government Operations segment produces naval nuclear reactors and fuel for the U.S. Naval Nuclear Propulsion Program, while the Commercial Operations segment designs and manufactures commercial nuclear steam generators, heat exchangers, pressure vessels, reactor components, and other auxiliary equipment, including containers for the storage of spent nuclear fuel and other high-level nuclear waste. The majority of the company's revenue comes from Government Operations, with sales principally in the United States, Canada, and other regions.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: